{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-001745","form_type":"8-K","ticker":"JANX","cik":"0001817713","company_name":"Janux Therapeutics, Inc.","filed_at":"2021-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.817444+00:00","generated_at":"2026-06-29T04:55:29.456826+00:00","sec_items":["5.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Janux Therapeutics appoints Ronald Barrett and Alana McNulty as directors","bullets":["Ronald Barrett, Ph.D. appointed as Class I director with term expiring at 2022 annual meeting.","Alana McNulty appointed as Class II director with term expiring at 2023 annual meeting.","Each receives $40,000 annual cash retainer and option to purchase 30,000 shares vesting over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-001745","json":"https://secwatch.observer/filing/0000950170-21-001745.json","markdown":"https://secwatch.observer/filing/0000950170-21-001745.md","text":"https://secwatch.observer/filing/0000950170-21-001745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/janx-20210907.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:55:29.456826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"627bef7d24","claim":"Alana McNulty was appointed as Class II director at Janux Therapeutics, Inc..","evidence_excerpt":"appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"d5a2d275e2","claim":"Ronald Barrett was appointed as Class I director at Janux Therapeutics, Inc..","evidence_excerpt":"appointed (i) Ronald Barrett, Ph.D. as a Class I director of the Company, with a term of office expiring at the 2022 annual meeting of stockholders, and (ii) Alana McNulty as a Class II director of the Company, with a term of office expiring at the 2023 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817713/000095017021001745/0000950170-21-001745-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}